{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:24:41Z","timestamp":1792758281052,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Opinion statement<\/jats:title><jats:p>Since total neoadjuvant treatment achieves almost 30% pathologic complete response, organ preservation has been increasingly debated for good responders after neoadjuvant treatment for patients diagnosed with rectal cancer. Two organ preservation strategies are available: a <jats:italic>watch and wait<\/jats:italic> strategy and a local excision strategy including patients with a near clinical complete response. A major issue is the selection of patients according to the initial tumor staging or the response assessment. Despite modern imaging improvement, identifying complete response remains challenging. A better selection could be possible by radiomics analyses, exploiting numerous image features to feed data characterization algorithms. The subsequent step is to include baseline and\/or pre-therapeutic MRI, PET-CT, and CT radiomics added to the patients\u2019 clinicopathological data, inside machine learning (ML) prediction models, with predictive or prognostic purposes. These models could be further improved by the addition of new biomarkers such as circulating tumor biomarkers, molecular profiling, or pathological immune biomarkers.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s11864-023-01125-9","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T06:02:32Z","timestamp":1694584952000},"page":"1507-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Crying Need for a Better Response Assessment in Rectal Cancer"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-5251","authenticated-orcid":false,"given":"Samuel","family":"Amintas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Denost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Garant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Frulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Dabernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638\u201346.","journal-title":"N Engl J Med"},{"key":"1125_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0140-6736(93)90207-W","volume":"341","author":"JK MacFarlane","year":"1993","unstructured":"MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457\u201360.","journal-title":"Lancet"},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.dld.2017.01.152","volume":"49","author":"J-P G\u00e9rard","year":"2017","unstructured":"G\u00e9rard J-P, Andr\u00e9 T, Bibeau F, et al. Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2017;49:359\u201367.","journal-title":"Dig Liver Dis"},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333.","journal-title":"J Clin Oncol"},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2003.09.032","volume":"40","author":"JF Bosset","year":"2004","unstructured":"Bosset JF, Calais G, Daban A, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Eur J Cancer. 2004;40:219\u201324.","journal-title":"Eur J Cancer"},{"key":"1125_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29\u201342.","journal-title":"Lancet Oncol"},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset J-F, Etienne P-L, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702\u201315.","journal-title":"Lancet Oncol"},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/SLA.0b013e3181dae4ed","volume":"251","author":"BC Paun","year":"2010","unstructured":"Paun BC, Cassie S, MacLean AR, et al. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251:807\u201318.","journal-title":"Ann Surg"},{"key":"1125_CR9","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","volume":"23","author":"KCMJ Peeters","year":"2005","unstructured":"Peeters KCMJ. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients\u2013a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"1125_CR10","first-page":"309","volume":"CXXII","author":"A Habr-Gama","year":"2004","unstructured":"Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Trans Meeting Am Surg Assocs. 2004;CXXII:309\u201316.","journal-title":"Trans Meeting Am Surg Assocs"},{"key":"1125_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1470-2045(19)30004-X","volume":"20","author":"E Rullier","year":"2019","unstructured":"Rullier E, Perez RO. Surgery or a watch-and-wait approach for rectal cancer? Lancet Oncol. 2019;20:189\u201390.","journal-title":"Lancet Oncol"},{"key":"1125_CR12","first-page":"9","volume":"3","author":"C Gani","year":"2017","unstructured":"Gani C, Bonomo P, Zwirner K, et al. Organ preservation in rectal cancer \u2013 challenges and future strategies. Clin Transl Radiat Oncol. 2017;3:9\u201315.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/bjs.8732","volume":"99","author":"R Glynne-Jones","year":"2012","unstructured":"Glynne-Jones R, Hughes R. Critical appraisal of the \u2018wait and see\u2019 approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99:897\u2013909.","journal-title":"Br J Surg"},{"key":"1125_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10151-019-02049-z","volume":"23","author":"A Arezzo","year":"2019","unstructured":"Arezzo A, Lo Secco G, Passera R, et al. Individual participant data pooled-analysis of risk factors for recurrence after neoadjuvant radiotherapy and transanal local excision of rectal cancer: the PARTTLE study. Tech Coloproctol. 2019;23:831\u201342.","journal-title":"Tech Coloproctol"},{"key":"1125_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ijrobp.2013.12.012","volume":"88","author":"A Habr-Gama","year":"2014","unstructured":"Habr-Gama A, Gama-Rodrigues J, S\u00e3o Juli\u00e3o GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1125_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/DCR.0000000000002494","volume":"66","author":"LM Fernandez","year":"2023","unstructured":"Fernandez LM, S\u00e3o Juli\u00e3o GP, Renehan AG, et al. The Risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database. Dis Colon Rectum. 2023;66:41\u20139.","journal-title":"Dis Colon Rectum"},{"key":"1125_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0140-6736(17)31056-5","volume":"390","author":"E Rullier","year":"2017","unstructured":"Rullier E, Rouanet P, Tuech J-J, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390:469\u201379.","journal-title":"Lancet"},{"key":"1125_CR18","doi-asserted-by":"publisher","unstructured":"\u2022\u2022\u00a0Rullier E, Vendrely V, Asselineau J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465\u2013474.\u00a0https:\/\/doi.org\/10.1016\/S2468-1253(19)30410-8. The only prospective randomized trial comparing TME and rectal preservation in good responders after chemoradiation for T2\/3 rectal cancers.","DOI":"10.1016\/S2468-1253(19)30410-8"},{"key":"1125_CR19","doi-asserted-by":"publisher","first-page":"20160665","DOI":"10.1259\/bjr.20160665","volume":"90","author":"RTHM Larue","year":"2017","unstructured":"Larue RTHM, Defraene G, De Ruysscher D, et al. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. BJR. 2017;90:20160665.","journal-title":"BJR"},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.csbj.2014.11.005","volume":"13","author":"K Kourou","year":"2015","unstructured":"Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8\u201317.","journal-title":"Comput Struct Biotechnol J"},{"key":"1125_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13244-019-0832-5","volume":"11","author":"E Montagnon","year":"2020","unstructured":"Montagnon E, Cerny M, Cadrin-Ch\u00eanevert A, et al. Deep learning workflow in radiology: a primer. Insights Imaging. 2020;11:22.","journal-title":"Insights Imaging"},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1007\/s00261-019-02042-y","volume":"44","author":"N Horvat","year":"2019","unstructured":"Horvat N, Bates DDB, Petkovska I. Novel imaging techniques of rectal cancer: what do radiomics and radiogenomics have to offer? A literature review Abdom Radiol. 2019;44:3764\u201374.","journal-title":"A literature review Abdom Radiol"},{"key":"1125_CR23","doi-asserted-by":"publisher","unstructured":"Cui Y, Liu H, Ren J, et al. Development and validation of a MRI-based radiomics signature for prediction of KRAS mutation in rectal cancer. Eur Radiol. 2020;30(4):1948-1958.\u00a0https:\/\/doi.org\/10.1007\/s00330-019-06572-3.","DOI":"10.1007\/s00330-019-06572-3"},{"key":"1125_CR24","doi-asserted-by":"publisher","first-page":"913683","DOI":"10.3389\/fonc.2022.913683","volume":"12","author":"Y Qin","year":"2022","unstructured":"Qin Y, Zhu L-H, Zhao W, et al. Review of radiomics- and dosiomics-based predicting models for rectal cancer. Front Oncol. 2022;12:913683.","journal-title":"Front Oncol"},{"key":"1125_CR25","doi-asserted-by":"crossref","unstructured":"Chen L-D, Li W, Xian M-F, et al. Preoperative prediction of tumour deposits in rectal cancer by an artificial neural network\u2013based US radiomics model. Eur Radiol 2019","DOI":"10.1007\/s00330-019-06558-1"},{"key":"1125_CR26","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00330-018-5683-9","volume":"29","author":"Y Cui","year":"2019","unstructured":"Cui Y, Yang X, Shi Z, et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2019;29:1211\u201320.","journal-title":"Eur Radiol"},{"key":"1125_CR27","doi-asserted-by":"publisher","unstructured":"Bibault JE, Giraud P, Housset M, et al. Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.\u00a0\u00a0Sci Rep. 2018;8(1):12611.\u00a0https:\/\/doi.org\/10.1038\/s41598-018-30657-6","DOI":"10.1038\/s41598-018-30657-6"},{"key":"1125_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13014-019-1246-8","volume":"14","author":"SH Jeon","year":"2019","unstructured":"Jeon SH, Song C, Chie EK, et al. Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer. Radiat Oncol. 2019;14:43.","journal-title":"Radiat Oncol"},{"key":"1125_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/RLI.0000000000000116","volume":"50","author":"CN De Cecco","year":"2015","unstructured":"De Cecco CN, Ganeshan B, Ciolina M, et al. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. Investig Radiol. 2015;50:239\u201345.","journal-title":"Investig Radiol"},{"key":"1125_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11547-018-0951-y","volume":"124","author":"L Boldrini","year":"2019","unstructured":"Boldrini L, Cusumano D, Chiloiro G, et al. Delta radiomics for rectal cancer response prediction with hybrid 035 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. Radiol med. 2019;124:145\u201353.","journal-title":"Radiol med"},{"key":"1125_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00259-017-3855-5","volume":"45","author":"P Lovinfosse","year":"2018","unstructured":"Lovinfosse P, Polus M, Van Daele D, et al. FDG PET\/CT radiomics for predicting the outcome of locally advanced rectal cancer. Eur J Nucl Med Mol Imaging. 2018;45:365\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1125_CR32","doi-asserted-by":"crossref","unstructured":"Liu Z, Zhang X-Y, Shi Y-J, et al. Radiomics Analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin Cancer Res. 2017;23:7253\u201362. First large-scale study assessing the interest of radiomics analysis for neoadjuvant radiochemotherapy treatment response evaluation in rectal cancer.","DOI":"10.1158\/1078-0432.CCR-17-1038"},{"key":"1125_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1148\/radiol.2017161375","volume":"284","author":"S Gourtsoyianni","year":"2017","unstructured":"Gourtsoyianni S, Doumou G, Prezzi D, et al. Primary Rectal cancer: repeatability of global and local-regional MR imaging texture features. Radiology. 2017;284:552\u201361.","journal-title":"Radiology"},{"key":"1125_CR34","doi-asserted-by":"crossref","unstructured":"Hu P, Wang J, Zhong H, et al. Reproducibility with repeat CT in radiomics study for rectal cancer. Oncotarget 2016 ; 7","DOI":"10.18632\/oncotarget.12199"},{"key":"1125_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejmp.2019.04.009","volume":"61","author":"A Traverso","year":"2019","unstructured":"Traverso A, Kazmierski M, Shi Z, et al. Stability of radiomic features of apparent diffusion coefficient (ADC) maps for locally advanced rectal cancer in response to image pre-processing. Physica Med. 2019;61:44\u201351.","journal-title":"Physica Med"},{"key":"1125_CR36","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1148\/rg.2017170077","volume":"37","author":"G Chartrand","year":"2017","unstructured":"Chartrand G, Cheng PM, Vorontsov E, et al. Deep learning: a primer for radiologists. Radiographics. 2017;37:2113\u201331.","journal-title":"Radiographics"},{"key":"1125_CR37","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s00066-020-01663-3","volume":"196","author":"P Lohmann","year":"2020","unstructured":"Lohmann P, Bousabarah K, Hoevels M, et al. Radiomics in radiation oncology-basics, methods, and limitations. Strahlenther Onkol. 2020;196:848\u201355.","journal-title":"Strahlenther Onkol"},{"key":"1125_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.canrad.2020.01.011","volume":"24","author":"J-E Bibault","year":"2020","unstructured":"Bibault J-E, Xing L, Giraud P, et al. Radiomics: a primer for the radiation oncologist. Cancer Radiother. 2020;24:403\u201310.","journal-title":"Cancer Radiother"},{"key":"1125_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1125_CR40","first-page":"1463","volume":"22","author":"S Stojanovic-Rundic","year":"2017","unstructured":"Stojanovic-Rundic S, Jankovic R, Micev M, et al. p21 does, but p53 does not predict pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. J Buon. 2017;22:1463\u201370.","journal-title":"J Buon"},{"key":"1125_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s10350-004-6524-2","volume":"46","author":"RPM Saw","year":"2003","unstructured":"Saw RPM, Morgan M, Koorey D, et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum. 2003;46:192\u2013202.","journal-title":"Dis Colon Rectum"},{"key":"1125_CR42","doi-asserted-by":"crossref","unstructured":"Chen M-B, Wu X-Y, Yu R, et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One 2012; 7.","DOI":"10.1371\/journal.pone.0045388"},{"key":"1125_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ijc.32507","volume":"146","author":"F Sclafani","year":"2020","unstructured":"Sclafani F, Wilson SH, Cunningham D, et al. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. Int J Cancer. 2020;146:94\u2013102.","journal-title":"Int J Cancer"},{"key":"1125_CR44","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1245\/s10434-016-5205-4","volume":"23","author":"OS Chow","year":"2016","unstructured":"Chow OS, Kuk D, Keskin M, et al. KRAS and combined KRAS\/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy. Ann Surg Oncol. 2016;23:2548\u201355.","journal-title":"Ann Surg Oncol"},{"key":"1125_CR45","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/j.clcc.2018.07.003","volume":"17","author":"CR Oh","year":"2018","unstructured":"Oh CR, Kim JE, Kang J, et al. Prognostic value of the microsatellite instability status in patients with stage II\/III rectal cancer following upfront surgery. Clin Colorectal Cancer. 2018;17:e679\u201385.","journal-title":"Clin Colorectal Cancer"},{"key":"1125_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13304-019-00697-2","volume":"72","author":"T Acar","year":"2020","unstructured":"Acar T, Acar N, Kamer E, et al. Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment? Updates Surg. 2020;72:73\u201382.","journal-title":"Updates Surg"},{"key":"1125_CR47","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/SLA.0000000000003051","volume":"271","author":"S Hasan","year":"2020","unstructured":"Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a National Cancer Database (NCDB) Analysis. Ann Surg. 2020;271:716\u201323.","journal-title":"Ann Surg"},{"key":"1125_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01216-3","volume":"7","author":"M Mi","year":"2022","unstructured":"Mi M, Ye C, Yuan Y. Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair\u2013deficient, locally advanced rectal cancer. Sig Transduct Target Ther. 2022;7:1\u20133.","journal-title":"Sig Transduct Target Ther"},{"key":"1125_CR49","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363\u201376.","journal-title":"N Engl J Med"},{"key":"1125_CR50","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. The Lancet. 2018;391:2128\u201339.","journal-title":"The Lancet"},{"key":"1125_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.21614\/chirurgia.114.2.152","volume":"114","author":"G Zeitoun","year":"2019","unstructured":"Zeitoun G, Sissy CE, Kirilovsky A, et al. The Immunoscore in the clinical practice of patients with colon and rectal cancers. Chirurgia (Bucur). 2019;114:152\u201361.","journal-title":"Chirurgia (Bucur)"},{"key":"1125_CR52","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-20-0337","volume":"26","author":"C El Sissy","year":"2020","unstructured":"El Sissy C, Kirilovsky A, Van den Eynde M, et al. A diagnostic biopsy-adapted Immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020;26:5198\u2013207.","journal-title":"Clin Cancer Res"},{"key":"1125_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","volume":"2","author":"F Dossa","year":"2017","unstructured":"Dossa F, Chesney TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1125_CR54","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S2468-1253(18)30301-7","volume":"3","author":"SA Chadi","year":"2018","unstructured":"Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:825\u201336.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1125_CR55","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/DCR.0b013e3181f42b89","volume":"53","author":"A Habr-Gama","year":"2010","unstructured":"Habr-Gama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692\u20138.","journal-title":"Dis Colon Rectum"},{"key":"1125_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2006.04.012","volume":"80","author":"K Bujko","year":"2006","unstructured":"Bujko K, Kepka L, Michalski W, et al. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol. 2006;80:4\u201312.","journal-title":"Radiother Oncol"},{"key":"1125_CR57","doi-asserted-by":"publisher","unstructured":"Patel UB, Brown G, Rutten H, et al.\u00a0Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol. 2012;19(9):2842\u201352.\u00a0https:\/\/doi.org\/10.1245\/s10434-012-2309-3","DOI":"10.1245\/s10434-012-2309-3"},{"key":"1125_CR58","doi-asserted-by":"publisher","unstructured":"Lambregts DM, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol. 2011;18(8):2224\u201331.\u00a0https:\/\/doi.org\/10.1245\/s10434-011-1607-5.","DOI":"10.1245\/s10434-011-1607-5"},{"key":"1125_CR59","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1002\/cncr.26644","volume":"118","author":"RO Perez","year":"2011","unstructured":"Perez RO, Habr-Gama A, Gama-Rodrigues J, et al. Accuracy of positron emission tomography\/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation. Cancer. 2011;118:3501\u201311.","journal-title":"Cancer"},{"key":"1125_CR60","first-page":"1241","volume":"47","author":"GL Cascini","year":"2006","unstructured":"Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241\u20138.","journal-title":"J Nucl Med"},{"key":"1125_CR61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.radonc.2014.11.026","volume":"113","author":"I Joye","year":"2014","unstructured":"Joye I, Deroose CM, Vandecaveye V, et al. The role of diffusion-weighted MRI and 18F-FDG PET\/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review. Radiother Oncol. 2014;113:158\u201365.","journal-title":"Radiother Oncol"},{"key":"1125_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/codi.14361","volume":"20","author":"The 2017 European Society of Coloproctology (ESCP) collaborating group","year":"2017","unstructured":"The 2017 European Society of Coloproctology (ESCP) collaborating group. Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery. Colorectal Dis. 2017;20:58\u201368.","journal-title":"Colorectal Dis"},{"key":"1125_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12032-017-1037-8","volume":"34","author":"G Colloca","year":"2017","unstructured":"Colloca G, Venturino A, Vitucci P. Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis. Med Oncol. 2017;34:177.","journal-title":"Med Oncol"},{"key":"1125_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3393\/ac.2018.10.01","volume":"35","author":"BH Jeon","year":"2019","unstructured":"Jeon BH, Shin US, Moon SM, et al. Neutrophil to lymphocyte ratio: a predictive marker for treatment outcomes in patients with rectal cancer who underwent neoadjuvant Chemoradiation followed by surgery. Ann Coloproctol. 2019;35:100\u20136.","journal-title":"Ann Coloproctol"},{"key":"1125_CR65","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41416-020-0941-4","volume":"123","author":"S Murahashi","year":"2020","unstructured":"Murahashi S, Akiyoshi T, Sano T, et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer. 2020;123:803\u201310.","journal-title":"Br J Cancer"},{"key":"1125_CR66","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Khakoo S, Carter PD, Brown G, et al. MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clin Cancer Res. 2020;26:183\u201392. The largest study assessing whether circulating tumor DNA might be an early indicator of tumor response or progression in rectal cancer.","DOI":"10.1158\/1078-0432.CCR-19-1996"},{"key":"1125_CR67","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1186\/s12885-015-1989-z","volume":"15","author":"S Hinz","year":"2015","unstructured":"Hinz S, R\u00f6der C, Tepel J, et al. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. BMC Cancer. 2015;15:953.","journal-title":"BMC Cancer"},{"key":"1125_CR68","doi-asserted-by":"publisher","first-page":"69507","DOI":"10.18632\/oncotarget.10875","volume":"7","author":"W Sun","year":"2016","unstructured":"Sun W, Li G, Wan J, et al. Circulating tumor cells: a promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016;7:69507\u201317.","journal-title":"Oncotarget"},{"key":"1125_CR69","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00384-012-1584-6","volume":"28","author":"JH Lee","year":"2013","unstructured":"Lee JH, Kim SH, Jang HS, et al. Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. Int J Colorectal Dis. 2013;28:511\u20137.","journal-title":"Int J Colorectal Dis"},{"key":"1125_CR70","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ijrobp.2008.08.057","volume":"74","author":"JW Park","year":"2009","unstructured":"Park JW, Lim S-B, Kim DY, et al. Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys. 2009;74:810\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1125_CR71","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/DCR.0b013e31819ef76b","volume":"52","author":"RO Perez","year":"2009","unstructured":"Perez RO, S\u00e3o Juli\u00e3o GP, Habr-Gama A, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum. 2009;52:1137\u201343.","journal-title":"Dis Colon Rectum"},{"key":"1125_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1245\/s10434-014-3962-5","volume":"22","author":"JH Lee","year":"2015","unstructured":"Lee JH, Hyun JH, Kim DY, et al. The role of fibrinogen as a predictor in preoperative chemoradiation for rectal cancer. Ann Surg Oncol. 2015;22:209\u201315.","journal-title":"Ann Surg Oncol"},{"key":"1125_CR73","doi-asserted-by":"publisher","unstructured":"Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. Sci Rep. 2017;7(1):16717.\u00a0https:\/\/doi.org\/10.1038\/s41598-017-16955-5.\u00a0","DOI":"10.1038\/s41598-017-16955-5"},{"key":"1125_CR74","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1186\/s12885-018-5022-1","volume":"18","author":"C Belluco","year":"2018","unstructured":"Belluco C, Forlin M, Delrio P, et al. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients. BMC Cancer. 2018;18:1094.","journal-title":"BMC Cancer"},{"key":"1125_CR75","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s12029-018-0173-5","volume":"50","author":"A Policicchio","year":"2019","unstructured":"Policicchio A, Mercier J, Digklia A, et al. Platelet and neutrophil counts as predictive markers of neoadjuvant therapy efficacy in rectal cancer. J Gastrointest Cancer. 2019;50:894\u2013900.","journal-title":"J Gastrointest Cancer"},{"key":"1125_CR76","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/ijc.32274","volume":"145","author":"M Diefenhardt","year":"2019","unstructured":"Diefenhardt M, Hofheinz R-D, Martin D, et al. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO\/ARO\/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer. 2019;145:2282\u201391.","journal-title":"Int J Cancer"},{"key":"1125_CR77","doi-asserted-by":"crossref","unstructured":"Dudani S, Marginean H, Tang PA, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer 2019 ; 19 .","DOI":"10.1186\/s12885-019-5892-x"},{"key":"1125_CR78","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10147-017-1105-2","volume":"22","author":"L Cabel","year":"2017","unstructured":"Cabel L, Proudhon C, Gortais H, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017;22:421\u201330.","journal-title":"Int J Clin Oncol"},{"key":"1125_CR79","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2217\/fon.13.91","volume":"9","author":"W Sun","year":"2013","unstructured":"Sun W, Huang T, Li G, et al. The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer. Future Oncol. 2013;9:1489\u2013500.","journal-title":"Future Oncol"},{"key":"1125_CR80","doi-asserted-by":"publisher","unstructured":"Magni E, Botteri E, Ravenda PS, et al. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int J Colorectal Dis. 2014;29(9):1053\u20139.\u00a0https:\/\/doi.org\/10.1007\/s00384-014-1958-z.","DOI":"10.1007\/s00384-014-1958-z"},{"key":"1125_CR81","doi-asserted-by":"crossref","unstructured":"Troncarelli Flores BC, Souza E Silva V, Ali Abdallah E, et al. Molecular and kinetic analyses of circulating tumor cells as predictive markers of treatment response in locally advanced rectal cancer patients. Cells 2019; 8","DOI":"10.3390\/cells8070641"},{"key":"1125_CR82","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.2147\/CMAR.S300554","volume":"13","author":"R-J Pan","year":"2021","unstructured":"Pan R-J, Hong H-J, Sun J, et al. Detection and clinical value of circulating tumor cells as an assisted prognostic marker in colorectal cancer patients. CMAR. 2021;13:4567\u201378.","journal-title":"CMAR"},{"key":"1125_CR83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1155\/2008\/598071","volume":"25","author":"M Zitt","year":"2008","unstructured":"Zitt M, M\u00fcller HM, Rochel M, et al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. 2008;25:159\u201365.","journal-title":"Dis Markers"},{"key":"1125_CR84","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/annonc\/mdx778","volume":"29","author":"JV Schou","year":"2018","unstructured":"Schou JV, Larsen FO, S\u00f8rensen BS, et al. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Ann Oncol. 2018;29:610\u20135.","journal-title":"Ann Oncol"},{"key":"1125_CR85","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/gutjnl-2017-315852","volume":"68","author":"J Tie","year":"2019","unstructured":"Tie J, Cohen JD, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2019;68:663\u201371.","journal-title":"Gut"},{"key":"1125_CR86","doi-asserted-by":"publisher","first-page":"103945","DOI":"10.1016\/j.ebiom.2022.103945","volume":"78","author":"W Liu","year":"2022","unstructured":"Liu W, Li Y, Tang Y, et al. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. EBioMedicine. 2022;78:103945.","journal-title":"EBioMedicine"},{"key":"1125_CR87","doi-asserted-by":"publisher","first-page":"1083285","DOI":"10.3389\/fonc.2023.1083285","volume":"13","author":"JM van Rees","year":"2023","unstructured":"van Rees JM, Wullaert L, Gr\u00fcter AAJ, et al. Circulating tumour DNA as biomarker for rectal cancer: a systematic review and meta-analyses. Front Oncol. 2023;13:1083285.","journal-title":"Front Oncol"},{"key":"1125_CR88","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","volume":"17","author":"A Dasari","year":"2020","unstructured":"Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17:757\u201370.","journal-title":"Nat Rev Clin Oncol"},{"key":"1125_CR89","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/cancers14040993","volume":"14","author":"U Strybel","year":"2022","unstructured":"Strybel U, Marczak L, Zeman M, et al. Molecular composition of serum exosomes could discriminate rectal cancer patients with different responses to neoadjuvant radiotherapy. Cancers (Basel). 2022;14:993.","journal-title":"Cancers (Basel)"},{"key":"1125_CR90","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-20-4769","volume":"27","author":"J Vidal","year":"2021","unstructured":"Vidal J, Casadevall D, Bellosillo B, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res. 2021;27:2890\u20138.","journal-title":"Clin Cancer Res"},{"key":"1125_CR91","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/sj.bjc.6602622","volume":"92","author":"E Lopez-Crapez","year":"2005","unstructured":"Lopez-Crapez E, Bibeau F, Th\u00e9zenas S, et al. p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis. Br J Cancer. 2005;92:2114\u201321.","journal-title":"Br J Cancer"},{"key":"1125_CR92","doi-asserted-by":"publisher","first-page":"574337","DOI":"10.3389\/fonc.2020.574337","volume":"10","author":"H-T Zhu","year":"2020","unstructured":"Zhu H-T, Zhang X-Y, Shi Y-J, et al. A deep learning model to predict the response to neoadjuvant chemoradiotherapy by the pretreatment apparent diffusion coefficient images of locally advanced rectal cancer. Front Oncol. 2020;10:574337.","journal-title":"Front Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01125-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T10:14:49Z","timestamp":1699870489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01125-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":92,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01125-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"9 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"V\u00e9ronique Vendrely declares payments for lectures by AMGEN, SERVIER, and BMS as well as support for attending a meeting by Kiowa Kyrin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}